Response to the Generic Drug Market and Sales Promotion
First written in FY2016. 22 of 38 entries say "Advanced", first in FY2020-Q3. Latest entry: 2026-08-10.
0 other companies' latest entry also says "Advanced".
- 2026-08-10AdvancedEarnings
「Under these circumstances, we worked to further establish our flagship products, including Kindaly dialysis agents for artificial kidneys, other dialysis-related products and pharmaceuticals, and infusions, while also focusing on promoting sales of generic drugs.」
The company continued to promote generic-drug sales and reported higher revenue due in part to the effectiveness of its sales-promotion activities. - FY2026AdvancedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs. As a result, for the fiscal year, net sales increased by ¥1,744 million, or 2.9%, year on year to ¥62,307 million, due in part to promoting generic drugs related to renal and dialysis care.」
The promotion of generic drugs related to renal and dialysis care and other factors were cited as drivers of full-year revenue growth, with revenue up 2.9% year on year. - 2026-05-12AdvancedEarnings
「As a result, driven by efforts to promote sales of generic drugs related to renal care and dialysis, revenue increased by ¥1,744 million, or 2.9%, year on year to ¥62,307 million.」
The promotion of generic-drug sales continued to be identified as a driver of full-year revenue growth. - FY2026-H1AdvancedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs. As a result, for the interim accounting period, net sales increased by ¥1,490 million, or 5.0%, year on year to ¥31,229 million, due in part to promoting generic drugs related to renal and dialysis care.」
Revenue increased 5.0% year on year, driven by the promotion of generic drugs related to renal and dialysis care and other factors. - FY2025AdvancedAnnual report
「Revenue increased to ¥6,056.3 million, up ¥515.5 million, or 9.3%, from the previous year, mainly due to the effects of promoting generic drugs related to renal and dialysis care and increased manufacturing and sales resulting from substitute supply of other companies' infusion and injectable products, among other factors.」
The promotion of generic drugs related to renal and dialysis care was explicitly identified, together with substitute supply of other companies' products, as a factor behind full-year revenue growth, with revenue up 9.3% year on year. - FY2025-H1AdvancedAnnual report
「Revenue increased to ¥2,973.9 million, up ¥231.4 million, or 8.4%, from the previous year, mainly due to the effects of promoting generic drugs related to renal and dialysis care and increased manufacturing and sales resulting from substitute supply of other companies' infusion and injectable products, among other factors.」
The promotion of generic drugs related to renal and dialysis care was explicitly identified, together with substitute supply of other companies' infusion and injectable products, as a factor behind the interim revenue growth, with revenue up 8.4% year on year. - FY2024AdvancedAnnual report
「As a result, for the fiscal year, revenue increased to ¥5,540.7 million, up ¥439.1 million, or 8.6%, from the previous fiscal year, mainly due to increased generic-drug sales and other factors.」
Full-year revenue increased 8.6% year on year, driven by increased generic-drug sales and other factors. - FY2024-Q3AdvancedAnnual report
「As a result, for the cumulative third quarter, revenue increased to ¥4,283.0 million, up ¥361.0 million, or 9.2%, from the same quarter of the previous year, mainly due to increased generic-drug sales and other factors.」
The company states that revenue for the cumulative third quarter increased 9.2% year on year, driven by increased generic-drug sales and other factors. - FY2024-Q2AdvancedAnnual report
「Under these circumstances, the company worked to strengthen market penetration for hemodialysis-related products, including its flagship Kindaly dialysis agent for artificial kidneys, as well as infusion products, while also focusing on promoting generic-drug sales. As a result, for the cumulative second quarter, revenue increased to ¥2,742.4 million, up ¥205.3 million, or 8.1%, from the same quarter of the previous year, mainly due to increased generic-drug sales and other factors.」
As a result of continuing to promote generic-drug sales, revenue for the cumulative second quarter increased 8.1% year on year to ¥2,742.4 million. - FY2024-Q1AdvancedAnnual report
「Under these circumstances, the company worked to strengthen market penetration for hemodialysis-related products, including its flagship Kindaly dialysis agent for artificial kidneys, as well as infusion products, while also focusing on promoting generic-drug sales. As a result, for the cumulative first quarter, revenue increased to ¥1,350.7 million, up ¥114.0 million, or 9.2%, from the same quarter of the previous year, mainly due to increased generic-drug sales and other factors.」
The company states that, as a result of focusing on promoting generic-drug sales, revenue for the cumulative first quarter increased 9.2% year on year. - FY2023AdvancedAnnual report
「As a result, for the fiscal year, revenue increased to ¥5,101.5 million, up ¥138.2 million, or 2.8%, from the previous fiscal year, mainly due to increased generic-drug sales and other factors.」
The company states that full-year revenue increased 2.8% year on year to ¥5,101.5 million, driven by increased generic-drug sales and other factors. - FY2023-Q3AdvancedAnnual report
「Under these circumstances, the company worked to strengthen market penetration for hemodialysis-related products, including its flagship Kindaly dialysis agent for artificial kidneys, as well as infusion products, while also focusing on promoting generic-drug sales. As a result, for the cumulative third quarter, revenue increased to ¥3,921.9 million, up ¥94.8 million, or 2.5%, from the same quarter of the previous year, mainly due to increased generic-drug sales and other factors.」
The company states that, as a result of focusing on promoting generic-drug sales, revenue for the cumulative third quarter increased 2.5% year on year. - FY2023-Q2AdvancedAnnual report
「Under these circumstances, the company worked to strengthen market penetration for hemodialysis-related products, including its flagship Kindaly dialysis agent for artificial kidneys, as well as infusion products, while also focusing on promoting generic-drug sales. As a result, for the cumulative second quarter, revenue increased to ¥2,537.1 million, up ¥40.4 million, or 1.6%, from the same quarter of the previous year, mainly due to increased generic-drug sales and other factors.」
The company states that, as a result of focusing on promoting generic-drug sales, revenue for the cumulative second quarter increased 1.6% year on year. - FY2023-Q1RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to promote generic-drug sales, but no new sales results or changes to its initiatives are disclosed. - FY2022AdvancedAnnual report
「Under these circumstances, the company worked to strengthen market penetration for hemodialysis-related products, including its flagship Kindaly dialysis agent for artificial kidneys, as well as infusion products, while also focusing on promoting generic-drug sales. As a result, for the fiscal year, revenue increased to ¥4,963.2 million, up ¥38.1 million, or 0.8%, from the previous fiscal year, mainly due to increased generic-drug sales and other factors.」
The company states that, as a result of continuing to promote generic-drug sales, full-year revenue increased 0.8% year on year. - FY2022-Q3AdvancedAnnual report
「Against this backdrop, for the cumulative third quarter, the pharmaceuticals business continued to focus on promoting generic-drug sales, as it had in the previous fiscal year. Revenue increased to ¥3,814.0 million, up ¥5.1 million, or 0.1%, from the same quarter of the previous year. However, gross profit decreased to ¥1,031.9 million, down ¥86.7 million, or 7.8%, as cost of sales increased to ¥2,782.0 million, up ¥91.8 million, or 3.4%, from the same quarter of the previous year.」
As a result of continuing to promote generic-drug sales, revenue from the pharmaceuticals business increased 0.1% year on year. Meanwhile, gross profit declined 7.8% due to higher cost of sales. - FY2022-Q2AdvancedAnnual report
「Against this backdrop, for the cumulative second quarter, the pharmaceuticals business continued to focus on promoting generic-drug sales, as it had in the previous fiscal year. Revenue increased to ¥2,487.9 million, up ¥3.3 million, or 0.1%, from the same quarter of the previous year.」
The company states that, as a result of continuing to promote generic-drug sales, revenue from the pharmaceuticals business increased 0.1% year on year. Revenue from generic drugs alone is not disclosed. - FY2022-Q1AdvancedAnnual report
「Against this backdrop, for the cumulative first quarter, the pharmaceuticals business continued to focus on promoting generic-drug sales, as it had in the previous fiscal year. Revenue increased to ¥1,255.6 million, up ¥16.8 million, or 1.4%, from the same quarter of the previous year. However, gross profit decreased by ¥28.9 million, or 7.7%, as cost of sales increased to ¥910.8 million, up ¥45.7 million, or 5.3%, from the same quarter of the previous year.」
As a result of continuing to promote generic-drug sales, revenue from the pharmaceuticals business increased 1.4% year on year. However, gross profit declined 7.7% due to higher cost of sales. - FY2021AdvancedAnnual report
「As a result, for the fiscal year, revenue increased to ¥4,925.1 million, up ¥234.9 million, or 5.0%, from the previous fiscal year, mainly due to increased generic-drug sales and other factors.」
Increased generic-drug sales and other factors were explicitly identified as drivers of full-year revenue growth, with revenue up 5.0% year on year. - FY2021-Q3AdvancedAnnual report
「For the cumulative third quarter, the pharmaceuticals business focused on promoting generic-drug sales, resulting in revenue growth of ¥1,980 million, or 5.5%, from the same quarter of the previous year.」
The company states that, as a result of focusing on promoting generic-drug sales, revenue from the pharmaceuticals business increased 5.5% year on year, or by ¥1,980 million. - FY2021-Q2RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to promote sales of generic drugs. - FY2021-Q1AdvancedAnnual report
「For the cumulative first quarter, the pharmaceuticals business focused on promoting generic-drug sales, resulting in revenue growth of ¥679 million, or 5.8%, from the same quarter of the previous year.」
The company states that, as a result of focusing on promoting generic-drug sales, revenue from the pharmaceuticals business increased 5.8% year on year. - FY2020AdvancedAnnual report
「As a result, for the fiscal year, net sales increased by ¥828 million, or 1.8%, year on year to ¥46,902 million, due to increased sales of generic drugs.」
Increased generic-drug sales were explicitly identified as a factor behind the full-year revenue growth, with revenue up 1.8% year on year. - FY2020-Q3AdvancedAnnual report
「As a result, for the cumulative third-quarter period, net sales increased by ¥607 million, or 1.7%, year on year to ¥36,229 million, due to increased sales of generic drugs.」
Increased generic drug sales were identified as a factor contributing to higher net sales for the cumulative third-quarter period, which increased 1.7% year on year. - FY2020-Q2RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2020-Q1RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to promote sales of generic drugs. - FY2019RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2019-Q3RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2019-Q2RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2019-Q1RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
As a response to the policy of expanding the generic drug market, the company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2018RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2018-Q3RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2018-Q1RestatedAnnual report
「Under these circumstances, we have sought to further strengthen market penetration of products related to hemodialysis, including Kindaly, our flagship dialysis solution for artificial kidneys, as well as infusion products, while also focusing on promoting sales of generic drugs.」
The company continues to promote sales of generic drugs. - FY2017RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2017-Q3RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2017-Q2RestatedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
The company continues sales activities focused on hospitals that have introduced DPC/PDPS. - FY2017-Q1RestatedAnnual report
「We have worked diligently to promote sales of generic drugs such as Naftopidil OD Tablets, a treatment for urinary disorders, and Levocarnitine Chloride Tablets, a treatment for carnitine deficiency.」
The company identifies several generic drugs and continues to promote their sales. - FY2016First statedAnnual report
「We will respond promptly to the government's policy of expanding the generic drug market and conduct proactive sales activities to encourage adoption of generic drugs, primarily at hospitals that have introduced the DPC/PDPS system (Diagnosis Procedure Combination/Per-Diem Payment System).」
In response to the policy of expanding the generic drug market, the company targets hospitals that have introduced DPC/PDPS as the focus of its sales activities.